Boston Scientific Corp BSX

$42.19 -0.21 (-0.50%)

Valuation

Market cap
61,737,196,000
Revenue TTM
$20,074,000,000
Net income TTM
$2,898,000,000
PE ratio
13.47
Forward PE
13.28
Profit margin
14.44%
Debt to equity
0.50

Trading

Volume
12,548,200
Avg volume
20,799,180
Day's range
$42.00 – $42.75
Shares out
1,449,230,000
Stochastic %K
12%
Beta
0.58
Analysts
Strong Sell
Price target
$58.81

Price

Company profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scop...

Show more

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Industry
Medical Devices
Sector
Healthcare
Phone
508 683 4000
Website
https://www.bostonscientific.com
Address
300 Boston Scientific Way, Marlborough, United States

Latest news

Stocktwits

FOUNDRY123 Oct 6, 10:49 PM
$BSX prediction - rises 1.02 percent in the AM and finishes the day ar -.42 percent. just a feeling
0 replies
Comox Oct 6, 9:59 PM
$BSX The confidence you have while pulling half this shit out of thin air is fucking impressive. “$35 after earnings” — source: trust me bro. “Top line won’t grow until 2028” — bro is apparently living in 2029 already. “Morale is at an all-time low” — did you personally interview every employee? You’ve turned every negative possibility into a guaranteed outcome and somehow think that makes you an analyst. At this point just short the fucking company and stop writing your breakup letter to BSX. And before you think I’m defending this shitshow — I fucking hate what BSX and this management team have been doing too. I just don’t confuse being pissed off with having a crystal ball.
1 replies
TricksterJones Oct 6, 9:59 PM
$BSX shittwits shows this up 14% in the AH. Checked Robinhood and it’s still sitting at $42. Thanks for the tease
0 replies
FiveKegs Oct 6, 8:42 PM
$BSX stock is going to drift lower and next stop after earnings is $35. Sales growth has slowed significantly Price will not rebound until the top line starts growing and that’s not until 2028 at the earliest Morale is at all time low. Massive headcount reduction going on so do you think that will lead to sales growth??? Take your cash somewhere else. Don’t fight reality
0 replies
rookie2016 Oct 6, 8:41 PM
$BSX we should hope someone like J&J buys this, I will take $59 a share right now.....and not look back....
0 replies
Tdorsey1776 Oct 6, 8:23 PM
$BSX When will the ship turn, not if. To me, thats the question.
0 replies
Badinvestor51 Oct 6, 7:54 PM
$BSX oh wow got to 42.17 almost had a small recovery god fucking forbid
0 replies
Badinvestor51 Oct 6, 7:29 PM
$BSX wow going below $40 probably. Just fucking nasty stock for a fucking nasty management team. Hey idiot, you’re down 6mm on your buy
0 replies